[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report].
A 65-year-old woman underwent radical operation for breast cancer in December, 1992. Between September, 1994 and January, 1997, she developed local recurrences four times as well as a supraclavicular lymph node recurrence. Each recurrence was treated with surgery and various types of chemoendocrine therapy, including anthracycline-containing chemotherapy. In April, 1997, she had developed a liver metastasis, which showed a partial response to docetaxel therapy. However, she developed a bone metastasis in January, 1998 (9 months after the initiation of docetaxel therapy). In addition to the docetaxel therapy, she was treated with a potent bisphosphonate, alendronate, 10 mg of which was infused every two weeks. Eight alendronate infusions resulted in a marked improvement in the bone metastasis, and the liver metastasis has been in regression for 13 months in response to the docetaxel therapy. In conclusion, alendronate is a promising agent against bone metastases which occur during docetaxel therapy for breast cancer.
Oura
S
S
1st Dept. of Surgery, Wakayama Medical College.
Sakurai
T
T
Yoshimura
G
G
Tamaki
T
T
Umemura
T
T
Kokawa
Y
Y
D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D000077143:Docetaxel; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D019386:Alendronate